PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease (INFLAMMATORY BOWEL DISEASES, 2009)

(untitled) - Bekker, P; Keshav, S; Johnson, D; Schall, T